Pathologic and Molecular Characterization of Branch Duct Intraductal Papillary Mucinous Neoplasm With Advanced Neoplasia Under-Recognized by Kyoto High-Risk Stigmata

OBJECTIVES: Kyoto high-risk stigmata (HRS) guide resection of branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) but miss a substantial proportion of high-grade dysplasia or invasive carcinoma (HGD/IC). We characterized the pathologic, molecular, and anatomic features of HGD/IC that Kyoto HRS fail to identify, and examined whether they are detectable before surgery by endoscopic ultrasound-guided needle-based confocal laser endomicroscopy (EUS-nCLE) and cyst-fluid molecular analysis. METHODS: BD-IPMNs resected from 2015 to 2024 in two prospective trials were retrospectively analyzed. Dysplasia and IPMN-subtype were reassessed by blinded pancreaticobiliary pathologists with consensus and immunohistochemistry. Papillary architecture was classified as macropapillary versus non-macropapillary (micropapillary or flat). Diagnostic performance for HGD/IC was assessed against the consensus pathology reference standard. RESULTS: Among 68 BD-IPMNs, 26 (38.2%) had HGD/IC, concentrated in non-macropapillary lesions (53.1%, 17/32, vs. 25.0%, 9/36; P=0.017), with the micropapillary pattern carrying the highest proportion (71.4%, 10/14). GNAS mutation was less frequent in non-macropapillary than macropapillary lesions (25.0% vs. 85.2%; P<0.001). Kyoto HRS were highly specific (95.2%) but only 53.8% sensitive; among 52 HRS-negative lesions, 23.1% (12/52) harbored HGD/IC, predominantly non-macropapillary, GNAS-negative, and located in the body or tail. Adding EUS-nCLE raised sensitivity from 52% to 80% (McNemar P=0.016) at 81% specificity, but nCLE was least sensitive in non-macropapillary lesions (43.8%), where absent GNAS provided a complementary preoperative marker. CONCLUSIONS: The HGD/IC missed by Kyoto HRS was characteristically micropapillary, GNAS-negative, and/or in the body or tail. Because architecture and subtype are histopathologic, preoperative recognition rests on combining Kyoto HRS, EUS-nCLE, and cyst-fluid molecular testing. Prospective external validation is warranted.

Authors

Institutions

Publication Details

Journal
Pancreas
Published
2026-11-13
DOI
https://doi.org/10.1097/mpa.0000000000002736
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pathologic and Molecular Characterization of Branch Duct Intraductal Papillary Mucinous Neoplasm With Advanced Neoplasia Under-Recognized by Kyoto High-Risk Stigmata

Stacey Culp, Tassiana G. Maloof, Zobeida Cruz‐Monserrate, Somashekar Gopala Krishna et al.
3 links
Pancreas
Pancreatic and Hepatic Oncology Research
article

Pathologic and Molecular Characterization of Branch Duct Intraductal Papillary Mucinous Neoplasm With Advanced Neoplasia Under-Recognized by Kyoto High-Risk Stigmata

Stacey Culp, Tassiana G. Maloof, Zobeida Cruz‐Monserrate, Somashekar Gopala Krishna, Phil A. Hart, Ashwini Kumar Esnakula, Zarine K. Shah, Timothy Michael Pawlik, Wendy L. Frankel, Jorge D. Machicado, Wei Chen, Ahmed Abdelbaki
article en

Abstract

OBJECTIVES: Kyoto high-risk stigmata (HRS) guide resection of branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) but miss a substantial proportion of high-grade dysplasia or invasive carcinoma (HGD/IC). We characterized the pathologic, molecular, and anatomic features of HGD/IC that Kyoto HRS fail to identify, and examined whether they are detectable before surgery by endoscopic ultrasound-guided needle-based confocal laser endomicroscopy (EUS-nCLE) and cyst-fluid molecular analysis. METHODS: BD-IPMNs resected from 2015 to 2024 in two prospective trials were retrospectively analyzed. Dysplasia and IPMN-subtype were reassessed by blinded pancreaticobiliary pathologists with consensus and immunohistochemistry. Papillary architecture was classified as macropapillary versus non-macropapillary (micropapillary or flat). Diagnostic performance for HGD/IC was assessed against the consensus pathology reference standard. RESULTS: Among 68 BD-IPMNs, 26 (38.2%) had HGD/IC, concentrated in non-macropapillary lesions (53.1%, 17/32, vs. 25.0%, 9/36; P=0.017), with the micropapillary pattern carrying the highest proportion (71.4%, 10/14). GNAS mutation was less frequent in non-macropapillary than macropapillary lesions (25.0% vs. 85.2%; P<0.001). Kyoto HRS were highly specific (95.2%) but only 53.8% sensitive; among 52 HRS-negative lesions, 23.1% (12/52) harbored HGD/IC, predominantly non-macropapillary, GNAS-negative, and located in the body or tail. Adding EUS-nCLE raised sensitivity from 52% to 80% (McNemar P=0.016) at 81% specificity, but nCLE was least sensitive in non-macropapillary lesions (43.8%), where absent GNAS provided a complementary preoperative marker. CONCLUSIONS: The HGD/IC missed by Kyoto HRS was characteristically micropapillary, GNAS-negative, and/or in the body or tail. Because architecture and subtype are histopathologic, preoperative recognition rests on combining Kyoto HRS, EUS-nCLE, and cyst-fluid molecular testing. Prospective external validation is warranted.

Pancreas
University of Michigan (US), The Ohio State University Wexner Medical Center (US), Michigan Medicine (US), The Ohio State University (US)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon